Distinguishing On-Target versus Off-Target Activity in Early Antibacterial Drug Discovery Using a Macromolecular Synthesis Assay
Mark L. Cunningham(Arcturus Therapeutics (United States)), Karen Joy Shaw(Arcturus Therapeutics (United States)), Kirk Nelson(Arcturus Therapeutics (United States)), Bryan P. Kwan(Arcturus Therapeutics (United States)), Daniel C. Bensen(State Street (United States))
Cited by 39
Related Papers
Comparative Genomic Analysis of Archaeal Genotypic Variants in a Single Population and in Two Different Oceanic Provinces
|Applied and Environmental Microbiology|2002|171
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity
|Bioorganic & Medicinal Chemistry Letters|2012|118
Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents
|PLoS ONE|2013|104
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity
|Bioorganic & Medicinal Chemistry Letters|2012|81
Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors
|Bioorganic & Medicinal Chemistry Letters|2006|37